Highlights
-
•
miRNAs play significant roles that can influence viral pathogenesis.
-
•
Studies Suggest that miRNAs related regulations influence dengue fever processes.
-
•
The involvement of miRNAs in antibody dependent enhancement is yet to be concluded.
Keywords: Dengue virus, Antibody-dependent enhancement, MicroRNA, Fcγ receptor, Host-directed therapy, miRNA biomarker
Abstract
Dengue virus is a major mosquito-borne pathogen that causes clinical manifestations ranging from asymptomatic infection to severe dengue, including dengue hemorrhagic fever and dengue shock syndrome. Disease severity is strongly associated with antibody-dependent enhancement (ADE), in which pre-existing non-neutralizing antibodies promote Fcγ receptor-mediated viral entry into immune cells, resulting in enhanced viral replication, immune dysregulation, endothelial dysfunction, and vascular leakage. Emerging evidence indicates that microRNAs (miRNAs) are key post-transcriptional regulators of host immune responses, inflammatory signaling, and vascular integrity during dengue virus infection. This review summarizes current evidence on the interplay between ADE and miRNA-mediated regulation of dengue pathogenesis, with emphasis on innate and adaptive immunity, Fcγ receptor signaling, cytokine responses, and endothelial barrier dysfunction. We also highlight circulating and tissue-specific miRNAs with potential value as biomarkers for disease severity and prognosis, and discuss emerging miRNA-based therapeutic strategies, including miRNA mimics and inhibitors, as host-directed approaches to modulate ADE-associated pathways. Improved understanding of miRNA regulatory networks may facilitate the development of novel biomarkers and targeted therapeutic strategies for severe dengue.
Graphical abstract

1. Introduction
Dengue virus (DENV), a member of the genus Flavivirus (family Flaviviridae), is the causative agent of dengue and remains one of the most prevalent mosquito-borne viral disease affecting humans worldwide.1, 2, 3 DENV is transmitted to humans mainly by bites of infected Aedes mosquitoes, especially Aedes aegypti and Aedes albopictus, which thrive in urban and peri‑urban settings and are also present in sylvatic environments.4, 5, 6 Its global incidence has risen markedly over recent decades, driven by urbanization, globalization and travel, and climate-related changes that expand vector suitability and seasonality; nearly half of the world’s population now lives in areas at risk of dengue transmission, underscoring the substantial social, economic, and healthcare burden of this disease.1,7
DENV exists as four genetically related yet antigenically distinct serotypes (DENV-1 to DENV-4).8 Infection with any serotype produces a wide spectrum of clinical manifestations, ranging from asymptomatic infection or mild febrile illness to classical dengue fever, and in severe cases, dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS).9 Historically, dengue was classified according to the 1997 WHO criteria as dengue fever, DHF, and DSS. The revised 2009 WHO classification categorizes cases as dengue without warning signs, dengue with warning signs (DWS), and severe dengue (SD). Throughout this review, the original terminology reported in the cited studies is retained where appropriate.1,10
Primary infection with a single serotype induces lifelong immunity against that specific serotype but provides only temporary cross-protection against the others. Consequently, secondary infection with a heterologous serotype increases the risk of severe disease, largely due to antibody-dependent enhancement (ADE).11 In ADE, pre-existing non-neutralizing or sub-neutralizing immunoglobulin G (IgG) antibodies form immune complexes that promote Fcγ receptor–mediated entry into susceptible immune cells, increasing infected-cell frequency and viral output. This can amplify viremia and skew innate and inflammatory signaling, contributing to dysregulated cytokine responses and endothelial dysfunction that ultimately drive vascular hyperpermeability and plasma leakage.12
DENV infection perturbs multiple host programs, including inflammation, immune modulation, apoptosis, and intracellular signaling pathways. MicroRNAs (miRNAs), small non-coding RNAs that post-transcriptionally regulate gene expression, have emerged as important regulators within these networks, shaping antiviral defenses and inflammatory homeostasis in ways that can influence disease severity under both direct infection and ADE- mediated conditions.13 Beyond host-pathway regulation, miRNAs may also affect dengue biology by interacting with viral RNA directly or by targeting host dependency factors required for replication. Depending on the cellular context, these interactions can either restrict or facilitate viral propagation.14 Circulating and vesicle-associated miRNAs have therefore attracted interest as candidate biomarkers for early risk stratification and prognosis in dengue.15
Despite growing evidence linking miRNAs to dengue immunopathogenesis, miRNA-mediated regulation specifically under ADE conditions remains comparatively underexplored, and many studies still address ADE mechanisms and miRNA regulation in parallel rather than as an integrated system.13 Accordingly, this review summarizes molecular mechanisms connecting ADE and miRNA-mediated regulation during DENV infection. We highlight how miRNAs may modulate immune signaling, inflammatory amplification, and endothelial dysfunction in both direct and ADE-mediated infection, discuss emerging miRNA-based diagnostic and therapeutic directions, and outline key gaps for future investigation.
2. Dengue pathogenesis and the role of antibody-dependent enhancement
DENV comprises four serologically related but genetically distinct serotypes—DENV-1, DENV-2, DENV-3, and DENV-4—each capable of causing disease in humans. More recently, reports have suggested the existence of a potential fifth serotype, DENV-5, highlighting the possibility of cross-species transmission from the sylvatic (non-human primate) cycle to humans, with potential implications for emerging outbreaks and vaccine development. All serotypes can infect humans, producing a wide clinical spectrum ranging from mild febrile illness to SD manifestations.16 Clinical outcomes are influenced by both viral factors (including serotype) and host factors such as age, genetic background, nutritional status, and pre-existing immunity. Infection with one serotype induces lifelong immunity against that serotype but does not confer protection against the others. Primary dengue infection typically occurs in individuals with no prior exposure and is usually self-limiting, often presenting with mild fever, headache, myalgia, or rash, followed by long-term immunity to the infecting serotype. In contrast, secondary infection with a heterologous serotype may result in more severe disease, including DHF and DSS.17 The enhanced severity in secondary infections has been linked to an immunopathological process in which pre-existing, cross-reactive, but non-neutralizing antibodies facilitate infection of Fc receptor-bearing immune cells, particularly monocytes, macrophages, and dendritic cells18 (Fig. 1A).
Fig. 1.

Primary vs. secondary dengue infection and ADE. (A) During primary infection with a DENV serotype (DENV1–4), clinical outcomes range from asymptomatic infection to mild febrile illness and, in some cases, SD, including DHF and DSS. Disease severity is influenced by viral factors (serotype) and host factors (e.g., age, genetic background, and nutritional status). During secondary infection with the same serotype, serotype-specific neutralizing antibodies result in life-long immunity. However, if the person is infected with a heterologous serotype and pre-existing antibodies are insufficiently neutralizing, they can contribute to ADE and higher chance of DHF and DSS. (B) Proposed mechanism of ADE during secondary dengue infection: sub-neutralizing, cross-reactive antibodies bind the heterologous virus and promote Fcγ receptor–mediated uptake into susceptible immune cells, leading to enhanced viral entry and higher replication. This can drive dysregulated cytokine responses (e.g. IL-6, TNF-α, and IFN-γ), contributing to endothelial dysfunction (vascular hyperpermeability and plasma leakage) culminating in severe clinical manifestations such as DHF and DSS.
Abbreviations: ADE, antibody-dependent enhancement; DENV, Dengue virus; DHF, dengue hemorrhagic fever; DSS, dengue shock syndrome; IFN, interferon; IL, interleukin; miRNA, microRNA; TNF-α, tumor necrosis factor-alpha
ADE is widely recognized as a central mechanism contributing to SD outcomes. During secondary infection, antibodies generated during the primary infection bind to the newly infecting serotype without neutralizing it, forming antibody–virus complexes that enhance viral entry into immune cells through Fcγ receptors (FcγR)s.18 This process increases viremia and promotes dysregulated immune activation, with elevated cytokine production—including interferon (IFN) -gamma, tumor necrosis factor-alpha (TNF-α), and interleukin (IL) −6—contributing to endothelial dysfunction, increased vascular permeability, and coagulation abnormalities. Experimental findings indicate that sera from individuals previously infected with one DENV serotype can enhance monocyte infection when challenged with a different serotype, supporting the ADE mechanism19 (Fig. 1B).
The ability of antibody–DENV immune complexes to enhance infection is not attributable to a single FcγR; rather, it is determined by the specific combination of activating and inhibitory FcγR subtypes expressed on myeloid target cells. Among myeloid cells, activating FcγR subtypes—including the high-affinity FcγRI (CD64) and the low-affinity FcγRIIa (CD32a) and FcγRIIIa (CD16a)—are co-expressed, signal through immunoreceptor tyrosine-based activation motifs (ITAMs), and mediate uptake of IgG–DENV immune complexes implicated in ADE. In contrast, FcγRIIb (CD32b) contains an immunoreceptor tyrosine-based inhibitory motif and functions as a negative regulator of FcγR-mediated signaling.20,21 In vitro studies using FcγR-transfected cell lines has demonstrated that activating FcγRs such as FcγRIIa and FcγRI are sufficient to mediate robust ADE of DENV infection, whereas coexpression of the inhibitory isoform FcγRIIb attenuates enhancement and viral output, indicating that FcγRII isoforms exert opposing effects on ADE.22 Clinical studies have shown that afucosylated anti-DENV IgG1 with increased affinity for FcγRIIIa is enriched in patients with DHF/DSS and associated with thrombocytopenia, and experimental models indicate that FcγRIIIa activation on splenic macrophages can exacerbate antibody-mediated dengue disease, consistent with a role for this activating receptor in amplifying ADE-associated pathology and resulting in inflammatory sequelae and mortality.23,24 Thus, the net strength of ADE in vivo is likely shaped not only by antibody characteristics but also by the relative expression and balance of activating (FcγRI, FcγRIIa, FcγRIIIa) vs. inhibitory (FcγRIIb) FcγR subtypes on susceptible immune cells, as well as host FcγR polymorphisms and tissue-specific differences in myeloid cell composition.20
Epidemiological studies further support the clinical relevance of ADE. Long-term cohort studies, particularly among children, have shown that intermediate levels of pre-existing anti-DENV antibodies are linked to a increased risk of SD than low (non-protective) or high (neutralizing) antibody levels, consistent with the ADE-associated “window of enhanced susceptibility”.25 In vitro studies demonstrate a characteristic “peak titer of enhancement,” where an optimal antibody concentration maximally enhances infection, while higher concentrations neutralize the virus.26,27 In vivo evidence was first demonstrated in rhesus monkeys, where administration of an anti-DENV monoclonal antibody (IgG 1A5) resulted in a 3- to 100-fold increase in viremia.28 Collectively, these findings indicate that severe secondary dengue is correlated with pre-existing anti-DENV antibody levels, primarily through ADE and modulated by host immune responses.
Beyond antibody titer alone, several qualitative properties of anti-DENV IgG jointly influence the magnitude of ADE. Antibody affinity and avidity are key parameters, IgG responses with low to intermediate functional neutralizing capacity can bind DENV particle without fully neutralizing it, favoring the formation of immune complexes that are efficiently captured by FcγRs, whereas high-affinity, strongly neutralizing antibodies tend to prevent FcγR-mediated uptake even at comparable titers.22,29 Epitope specificity also plays a central role, as cross-reactive antibodies directed against conserved but poorly accessible epitopes such as the fusion loop and prM are typically weakly neutralizing yet highly prone to mediate ADE, in contrast to antibodies targeting quaternary or type-specific epitopes that predominantly confer neutralization. Epitope specificity appears to be a major factor determining whether anti-DENV antibodies are protective or enhancing. Cross-reactive antibodies recognizing conserved fusion loop–like epitopes on E generally exhibit poor neutralizing activity and a higher tendency to drive ADE, in contrast to type specific antibodies directed against domain III or quaternary epitopes, which more often show strong neutralizing capacity and are mainly linked to protection.30 IgG subclass usage further modulates ADE in dengue, as epitope matched anti DENV antibodies of the IgG1 and IgG3 subclasses engage activating FcγRs more efficiently than their IgG2 and IgG4 counterparts, leading to subclass dependent differences in FcγR engagement and downstream responses in FcγR-expressing myeloid cells.31 Taken together, these observations indicate that ADE in dengue is not governed by antibody titre alone, but instead reflects the integrated effects of antibody concentration together with qualitative features of the humoral response, including IgG affinity, epitope specificity, subclass usage, and Fc glycosylation.22
3. MicroRNAs: biological functions and relevance in viral infections
miRNAs are endogenous, non-coding RNA molecules approximately 21–23 nucleotides long that serve as key post-transcriptional regulators of gene expression.32 By fine-tuning protein output, miRNAs help maintain signaling within physiological ranges and limit aberrant activation that can contribute to pathological states, including uncontrolled inflammation or cancer. Their biogenesis involves several tightly regulated steps that begin in the nucleus and are completed in the cytoplasm. Primary miRNA transcripts are first synthesized by RNA polymerase II and subsequently processed by the microprocessor complex, which includes the RNase III enzyme Drosha and the DiGeorge Critical Region 8 protein.33, 34, 35 Precise Drosha-mediated cleavage is essential, as even small processing errors can generate dysfunctional miRNAs that fail to regulate target genes effectively and may contribute to disease progression. This processing yields precursor miRNAs of about 60–70 nucleotides. The resulting precursor miRNAs are transported from the nucleus to the cytoplasm by Exportin-5, where they undergo further processing by the RNase III enzyme Dicer to generate mature double-stranded miRNAs approximately 18–21 nucleotides in length. Dicer processing also influences strand selection, helping determine which cellular pathways are regulated.36,37 One strand of this duplex, termed the guide strand, associates with an Argonaute protein to form the miRNA-induced silencing complex (miRISC), which mediates target recognition and gene silencing.32 The mature miRNA guides miRISC to complementary messenger RNA (mRNA) targets, while Argonaute recruits additional proteins that promote translational repression and/or mRNA degradation. Through this mechanism, miRNAs can dynamically adjust gene expression in response to cellular stress, infection, or developmental cues, maintaining homeostasis (Fig. 2A). Therefore, the biogenesis and activity of miRNAs must be precisely regulated at multiple levels to maintain appropriate control of gene expression.38
Fig. 2.

miRNA biogenesis and function, reported differential expression in dengue, and proposed roles in pathogenesis. (A) miRNA biogenesis and function: The guide strand of the mature miRNA duplex loads onto AGO to form miRISC, which mediates target recognition and gene silencing via translational repression and/or mRNA degradation. (B) Observed differences in miRNA: Dengue studies report altered miRNA profiles in infected patients vs. healthy controls, with stage- and outcome-associated signatures across asymptomatic, mild, and severe disease (DHF/DSS). (C) miRNA roles in dengue infection: miRNAs may modulate Fcγ receptor signaling and Fc-mediated entry, regulate clathrin-dependent endocytosis and vesicle trafficking, tune NF-κB/ mitogen-activated protein kinase (MAPK)-driven inflammatory responses, and influence autophagy and endothelial barrier integrity, processes linked to ADE, vascular hyperpermeability, and plasma leakage.
Abbreviations: ADE, antibody-dependent enhancement; AGO, Argonaute; DHF, dengue hemorrhagic fever; DSS, dengue shock syndrome; IFN, interferon; IL, interleukin; miRISC, miRNA-induced silencing complex; MAPK, mitogen-activated protein kinase; miRNA, microRNA; NF-κB, Nuclear factor kappa-light-chain-enhancer of activated B cells.
MiRNAs are central regulators of immune and inflammatory responses. Functionally, they act as molecular regulator, capable of dampening excessive immune activation or enhancing pathogen-specific responses as needed. Some miRNAs suppress inflammation, whereas others enhance immune activity by targeting negative regulators of immune signaling.39 In macrophages, key effector cells of the innate immune system, miR-125b promotes macrophage-mediated inflammation by targeting interferon regulatory factor 4 (IRF4), thereby augmenting immune responses and anti-tumor activity.40 In contrast, miR-147 functions as a negative regulator of inflammation by limiting excessive immune activation downstream of Toll-like receptor (TLR) signaling. This regulatory effect has been demonstrated for TLR2, TLR3, and TLR4 and involves both the MyD88- and TRIF-dependent signaling pathways.41 In clinical scenarios, dysregulation of these miRNAs has been linked to exaggerated cytokine storms in severe viral infections, highlighting their relevance in controlling immune-mediated tissue damage.42
Beyond innate immunity, miRNAs also play critical roles in adaptive immune regulation. They influence the activation, survival, differentiation, and proliferation of B and T lymphocytes.43 For instance, altered miRNA expression may affect vaccine responsiveness; insufficient miR-155 expression could blunt T-cell polarization and reduce immunization effectiveness. miR-155 is essential for CD4⁺ T-cell differentiation, and its overexpression drives polarization toward Th1 cells.44 Similarly, miR-150 facilitates the transition from pre-B to mature B cells by targeting c-Myb, a transcription factor necessary for normal B-cell development. This precise modulation helps the immune system generate high-affinity antibodies while limiting autoimmunity, a balance that is particularly relevant in viral infections such as dengue.39
The role of miRNAs extends beyond immune regulation to viral pathogenesis. Many viruses, including DENV, manipulate host miRNA expression to facilitate replication or evade immune detection. Conversely, certain host miRNAs exert antiviral effects, either by inhibiting viral replication directly or by restricting infection to latent states.15 During DENV infection, distinct alterations in miRNA expression have been observed. Upregulated miRNAs include miR-927, miR-87, miR-210, miR-2a-3p, miR-190, and miR-970, whereas miR-252, miR-263a-3p, miR-92b, miR-5R-109-5, miR-124, miR-286a, and miR-286b are reported to be downregulated.45 These expression changes influence the translation of both immune-related and cellular transcripts, ultimately affecting viral replication and immune modulation. miRNAs may either inhibit or promote DENV replication by targeting viral genomic regions or modulating host factors. For example, miR-281 has been shown to target the 5′ untranslated region of the DENV-2 genome, enhancing viral replication in response to infection. In contrast, overexpression of miR-484 and miR-744 inhibits DENV replication by acting on the 3′-untranslated regions of all four serotypes, suggesting that these miRNAs serve as host restriction factors against dengue infection.15 In clinical observations, patients with SD often exhibit dysregulated miRNA profiles, suggesting that miRNA patterns could serve as prognostic markers for disease severity and recovery trajectories. Overall, these findings highlight the potential of miRNAs as biomarkers for disease progression, therapeutic targets, and even as modulators for vaccine design.39
4. MicroRNA expression profiles in dengue infection
Host-derived miRNAs can suppress or facilitate viral replication by directly binding viral genomes or by regulating cellular genes involved in the viral replication. Beyond these functions, they mediate complex regulatory interactions between host and viral transcriptomes during infection. Viruses can to favor their own replication by exploiting host miRNAs to escape immune system and regulate host related transcription. This impact may occur either through direct binding to the RNA viral genome or through virus-induced changes in the host transcriptome. Researchers have found multiple miRNAs that affect DENV replication through direct targeting of viral genomic RNA.15
Using a miRNA PCR array in an observational case-control study, Ouyang and colleagues identified 53 dysregulated serum miRNAs in patients with DENV-1 infection, including 41 that were upregulated and 12 that were downregulated relative to healthy controls. Among the significantly altered miRNAs, hsa-miR-21-5p, hsa-miR-590-5p, hsa-miR-188-5p, and hsa-miR-152-3p exhibited increased expression, whereas hsa-miR-146a-5p showed reduced expression. It was also demonstrated that hsa-miR-21-5p and hsa-miR-146a-5p effectively differentiated dengue patients from healthy individuals, highlighting their potential utility as biomarkers for the early detection of dengue-associated inflammatory and pathological responses.46
Furthermore, studies analyzing miRNA expression in dengue patients demonstrate that circulating miRNAs can differentiate between various stages of dengue disease, with expression patterns strongly correlating with disease progression. Circulating miRNAs in blood, serum, and plasma therefore represent potential biomarkers for diagnosing dengue and assessing severity and may also be promising candidates for antiviral therapies.13 In an observational clinical study by Saini et al.,74, 38, and 25 differentially expressed miRNAs were identified in DWS, SD, and DWS and SD groups compared with the dengue infection (DI) group, respectively. Plasma profiling revealed significantly elevated expression of miR-6499 and miR-122 in patients with SD. Longitudinal analyses further identified nine miRNAs (miR-486-5p, miR-92a-5p, miR-320a, miR-151b, miR-191-5p, miR-584-5p, let-7i-5p, miR-92b-5p, and miR-378a-5p) whose expression patterns were closely associated with disease advancement. Among these, miR-486-5p, miR-92a-5p, miR-320a, and miR-191-5p were consistently dysregulated in both the DWS and SD groups compared with patients with DI. Notably, miR-122-5p demonstrated excellent discriminatory performance and was identified as a promising biomarker for distinguishing different phases of dengue disease.47
Several studies have demonstrated that miRNA expression profiles differ between patients with mild and severe dengue, suggesting that these molecules may contribute to disease progression and the development of specific complications. In one investigation, 17 candidate miRNAs were identified as potential biomarkers for dengue-associated complications. Among them, miR-24-1-5p, miR-512-5p, and miR-4640-3p effectively differentiated patients with uncomplicated dengue from those with liver involvement, while miR-383 expression was significantly higher in mild dengue than in patients who developed severe disease accompanied by plasma leakage and fluid accumulation.48 miR-574-5p and miR-1246 showed superior diagnostic performance in differentiating patients with SD from those with DI in an observational cohort study by Limothai et al. Additionally, miR-574-5p was implicated in TLR9 signaling, and DENV infection induces the release of mitochondrial DNA (mtDNA) into the cytosol and activates TLR9 signaling pathways, leading to the production of interferons (IFNs). miR-1246 has been linked to glycogen synthase kinase-3β-mediated Wnt/β-catenin signaling, and DENV-2 hinders glycogen synthase kinase-3 activity for induction of major histocompatibility complex Class-1-related chain A and B expression. Consistent with previous research, miR-122-5p was upregulated in SD and could be used to differentiate between different stages of dengue infection49 (Fig. 2B).
In humans, DENV replicates predominantly in dendritic cells, monocytes, macrophages, and hepatocytes; however, comprehensive miRNA profiling across these target cells remains limited. cell-type-specific miRNA responses to DENV were elucidated, and comparative analysis was performed across different cell types. Basal miRNA abundance varied substantially among hepatocytes (Huh7), lung epithelial cells (A549), and monocytic cells (THP1), with miR-486-5p predominantly expressed in A549 cells, miR-92a-2-5p, miR-320a-5p, and miR-191-5p enriched in THP1 cells, and miR-122 exclusively enriched in Huh7 hepatocytes. This cell-type specificity of miRNA responses suggests that differential miRNA networks in hepatocytes, immune cells, and epithelial cells contribute distinctly to viral replication dynamics and host immune activation during dengue infection.47
Beyond FcγR expression and ADE-related entry pathways, miRNAs also contribute to downstream inflammatory and endothelial responses central to SD pathogenesis.
During ADE, immune complex–FcγR engagement triggers excessive production of pro-inflammatory cytokines (TNF-α, IL-6, IL-8) that drives DHF pathogenesis. Host miRNAs critically regulate these inflammatory pathways through nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and MAPK signaling cascades.50 miR-146a plays a complex role in dengue pathogenesis. It dampens IFN-β production by targeting TRAF6, thereby acting as a proviral factor. Additionally, miR-146a inhibits DENV-induced autophagy, which reduces TNF-α and IL-6 secretion; conversely, miR-146a inhibition restores robust cytokine production.51,52 miR-30e* exerts antiviral effects by promoting NF-κB-dependent IFN-β production through targeting IκBα, thereby restricting viral replication.53 Critically, ADE-specific miRNA profiling reveals that the miRNA network is fundamentally altered compared to direct infection, with 50 miRNAs showing differential expression patterns. This miRNA-mediated inflammatory imbalance correlates with SD manifestations, including vascular permeability and endothelial dysfunction.50 miR-573 is significantly downregulated in DENV-2-infected endothelial cells due to decreased PPARγ activity; this downregulation leads to increased expression of angiopoietin-2 and TLR2, which promote vascular permeability and proinflammatory responses. Restoration of miR-573 levels significantly reduces endothelial hyperpermeability by suppressing angiopoietin-2 expression and protecting vascular endothelial cadherin junction integrity.54,55 miR-126 regulates angiogenic signaling by targeting negative regulators of the vascular endothelial growth factor pathway, including SPRED1 and PIK3R2, thereby enhancing endothelial responsiveness to vascular endothelial growth factor. However, its direct role in dengue-associated plasma leakage remains unclear, with some studies showing no correlation with acute vascular leakage.56,57 Table 1 summarizes the differential expression patterns, cellular sources, biological functions, and potential relevance to ADE of miRNAs reported in DENV infection.
Table 1.
Differentially expressed miRNAs reported in dengue virus infection according to sample source and cell type.
| Sample/ Cell Type | miRNA | Expression Change | Proposed Function | Relevance to ADE | Reference |
|---|---|---|---|---|---|
| Serum | miR-21-5P miR-590-5P miR-188-5p miR-152-3P |
Upregulated | Early inflammatory response biomarker | Indirect inflammatory regulation | 46 |
| Serum | miR-146a-5p | Downregulated | Early inflammatory response regulator | Indirect inflammatory regulation | 46 |
| Plasma | miR-122-5p | Upregulated | Severity and liver injury biomarker | Indirect disease-severity association | 47,49 |
| Plasma | miR-6499 | Upregulated | SD-associated marker | Indirect disease-severity association | 47 |
| Serum/Plasma | miR-574-5p | Upregulated | TLR-related inflammation | Indirect inflammatory regulation | 49 |
| Serum/Plasma | miR-1246 | Upregulated | SD biomarker | Indirect disease-severity association | 49 |
| Hepatocytes (Huh7) | miR-122 | Upregulated | Regulation of viral replication | Indirect antiviral regulation | 47 |
| Epithelial cells(A549) | miR-486-5p | Upregulated | Host immune activation | Indirect immune regulation | 47 |
| Monocytic cells (THP1) | miR-92a-2-5p miR-320a-5p miR-191-5p |
Upregulated | Cellular immune response | Indirect immune regulation | 47 |
| Macrophages | miR-24 miR-30b miR-142-3p |
Upregulated | Downregulation of FcγR expression | Direct FcγR regulation | 58 |
| Monocytes (THP-1) | miR-30a-5p miR-548c-5p miR-548d-5p miR-652-3p |
Upregulated | Regulation of FcγR-mediated viral entry | FcγR-associated signaling | 59 |
| PBMCs | miR-155 | Upregulated | Antibody production and immune regulation | Indirect immune regulation | 60 |
| PBMCs | miR-30e* | Upregulated | Promotes IFN-β Response |
Indirect antiviral regulation | 53 |
| Endothelial Cells | miR-573 | Downregulated | Maintains endothelial integrity | Indirect endothelial dysfunction/plasma leakage regulation | 55 |
| Endothelial Cells | miR-126 | Downregulated | Vascular homeostasis | Indirect endothelial dysfunction/plasma leakage regulation | 56,57 |
| PBMCs | miR-150-5p | Upregulated | Immune dysregulation marker | Indirect immune regulation | 61,62 |
| Hepatocytes | miR-122-5p | Upregulated | Associated with hepatic injury | Indirect disease-severity association | 63 |
| Serum/Plasma | miR-1303 | Upregulated | Linked to early plasma leakage and mucosal bleeding | Indirect endothelial dysfunction/plasma leakage regulation | 49 |
| PBMCs | hsa-miR-26b-5p hsa-miR-335-5p |
Downregulated | CXCR1 upregulation and inflammatory cell recruitment | Indirect immune regulation | 64 |
Abbreviations: ADE, antibody-dependent enhancement; FcγR Fcγ receptor; miRNA, microRNA; PBMC, Peripheral blood mononuclear cell; SD, severe dengue; TLR, Toll-like receptor.
miRNAs have emerged as important post-transcriptional regulators of pathways involved in ADE. Current evidence suggests that miRNAs influence ADE through direct regulation of FcγR expression, modulation of FcγR-associated signaling cascades, or indirect control of immune and endocytic processes that contribute to antibody-mediated viral entry. Based on the available mechanistic data, miRNAs implicated in ADE can be categorized according to the strength of supporting evidence.
Among the miRNAs with the strongest mechanistic support are miR-24, miR-30b, and miR-142-3p. Studies in human monocyte-derived macrophages demonstrated that these miRNAs directly target Fc receptor transcripts, resulting in reduced FcγR surface expression and diminished antibody-dependent antigen uptake. Experimental overexpression of these miRNAs decreases Fc receptor abundance and antibody-mediated internalization, whereas inhibition produces the opposite effect, confirming a direct regulatory role in FcγR expression and function.58 Although these studies were not performed in dengue-specific ADE models, they provide compelling evidence that miRNAs can directly modulate cellular susceptibility to FcγR-mediated uptake processes.
A second group of miRNAs, including miR-30a-5p, miR-548c-5p, miR-548d-5p, and miR-652-3p, is supported by moderate mechanistic evidence. These miRNAs have been identified in dengue infection models and are predicted or experimentally associated with pathways linked to Fc receptor signaling, cellular stress responses, apoptosis, transforming growth factor-βsignaling, and tropomyosin receptor kinase signaling. Notably, Fc receptor-mediated cytokine production during ADE relies on spleen tyrosine kinase, a signaling molecule that exhibits increased activity in monocytes undergoing antibody-enhanced DENV infection. Computational and functional analyses suggest that miR-30a-5p may regulate components of this signaling axis, thereby influencing ADE-associated immune activation.59 While direct targeting of FcγR transcripts has not been conclusively demonstrated for these miRNAs, their involvement in pathways downstream of FcγR engagement suggests a potential role in shaping ADE outcomes.65,66
Additional miRNAs have been implicated indirectly in ADE through their effects on antiviral immunity, antibody responses, or endocytic pathways. Among these, miR-155 plays a central role in B-cell differentiation, plasma cell development, and class-switched antibody production, processes that determine the quality and magnitude of humoral immune responses. However, to the best of our knowledge, no studies have directly demonstrated that specific miRNAs alter the neutralizing vs. enhancing activity, affinity, epitope specificity, or IgG subclass composition of DENV-specific antibodies. Therefore, any contribution of miRNAs to these antibody characteristics should currently be regarded as a proposed mechanism rather than an established determinant of ADE. miR-30e has been reported to suppress DENV replication by enhancing NF-κB-dependent interferon-β production, thereby influencing host antiviral defenses. Furthermore, miR-199a and miR-199b directly regulate components of the clathrin-mediated endocytic machinery, including clathrin heavy chain, dynamin, and Rab5A, which are essential for vesicular trafficking and viral internalization. Because ADE involves the uptake of antibody-virus immune complexes through Fc receptors followed by endocytic trafficking, regulation of these pathways by miRNAs may substantially affect the efficiency of antibody-enhanced infection.15,20,53,60,67,68
Collectively, these findings indicate that miRNAs regulate ADE at multiple levels, ranging from direct control of Fcγ receptor expression to modulation of intracellular signaling, antibody generation, antiviral responses, and endocytic trafficking. Nevertheless, much of the evidence outside FcγR regulation remains indirect, and direct experimental studies demonstrating how specific miRNAs influence DENV-specific enhancing vs. neutralizing antibody responses are currently lacking. Further mechanistic studies using physiologically relevant ADE models are required to establish causal relationships and evaluate the potential of these miRNAs as biomarkers or therapeutic targets for SD.
A summary of miRNAs implicated in Fcγ receptor signaling and ADE, categorized according to the strength of available mechanistic evidence, is provided in Table 2.
Table 2.
Classification of miRNAs implicated in FcγR signaling and antibody-dependent enhancement according to the level of mechanistic evidence.
| miRNA | Evidence in ADE models | FcγR-related evidence | Strength of evidence |
|---|---|---|---|
| miR-24 | No | Direct | Strong |
| miR-30b | No | Direct | Strong |
| miR-142-3p | No | Direct | Strong |
| miR-30a-5p | Yes | Indirect | Moderate |
| miR-548c-5p | Yes | Indirect | Moderate |
| miR-548d-5p | Yes | Indirect | Moderate |
| miR-652-3p | Yes | Indirect | Moderate |
| miR-155 | Yes | Indirect | Limited |
| miR-30e | Yes | Indirect | Limited |
| miR-199a/b | Yes | Indirect | Limited |
Abbreviations: ADE, antibody-dependent enhancement; FcγR, Fcγ receptor; miRNA, microRNA.
Detailed information regarding sample type, dengue infection context, ADE-related mechanisms, and supporting evidence for individual miRNAs is provided in Supplementary Table S1.
5. Therapeutic implications and future directions
The increasing recognition of miRNAs as key regulators of dengue pathogenesis—particularly in ADE—has opened new avenues for therapeutic intervention. Conventional antiviral strategies primarily target viral proteins.69 In contrast, miRNA-based approaches aim to modulate host pathways involved in viral entry, immune activation, inflammatory signaling, and endothelial dysfunction. This host-directed strategy may reduce viral replication and immunopathology while potentially lowering the risk of antiviral resistance.14,70 However, translating miRNA-related findings into clinically viable therapies remains challenging, given the complexity of ADE and the multifactorial nature of SD. Fig. 3 summarizes therapeutic implications and future directions of miRNA-based interventions for dengue.
Fig. 3.

Therapeutic implications and future directions of miRNA-based interventions for dengue. (A) Intervention targets: Key intervention targets involve dengue pathogenesis and antibody-dependent enhancement (ADE), including Fcγ receptor–mediated uptake, cytokine amplification, innate immune regulation, and endothelial barrier disruption and plasma leakage. (B) Approaches: Therapeutic modalities for miRNA modulation include miRNA inhibitors (to suppress pathogenic miRNAs upregulated in SD) and miRNA mimics (to restore protective miRNAs downregulated in SD). (C) Delivery: Representative delivery platforms for miRNA therapeutics such as lipid nanoparticles, polymeric nanoparticles, and exosome-like vesicles target toward major cellular compartments implicated in dengue severity, including monocytes/macrophages and the endothelium. (D) Personalization: A personalization pipeline for translation to clinical use, incorporating miRNA signature profiling, patient stratification (e.g., inhibitor-leaning vs. mimic-leaning strategies), and outcome monitoring to link molecular responses with clinical endpoints. (E) Limitations: Practical limitations and development considerations for miRNA therapeutics.
Abbreviations: ADE, antibody-dependent enhancement; FcγR Fcγ receptor; miRNA, microRNA; SD, severe dengue.
5.1. Targeting miRNAs to alter ADE-related pathways
Several miRNAs associated with dengue infection have been linked to ADE-related pathways, including FcγR signaling, cytokine production, endothelial permeability, and innate immune regulation. Modulating these miRNAs may reduce antibody-mediated viral entry into monocytes and macrophages, which are key targets during secondary dengue infection.67 For example, hsa-miR-574-5p and hsa-miR-1246, which are upregulated in SD, have been associated with plasma leakage, thrombocytopenia, and mucosal bleeding, suggesting that therapeutic inhibition (e.g., with antagomirs) could help attenuate endothelial dysfunction and systemic inflammation.49 miR-150-5p is also reported to be upregulated in severe disease and correlates with reduced SOCS1 and EZH2 expression in DHF patients, a pattern consistent with dysregulated immune responses; thus, antagomir-mediated suppression may restore cytokine signaling balance and mitigate immune overactivation.61,62 In addition, miR-122-5p, a liver-enriched miRNA, is elevated in plasma during SD and may reflect hepatic involvement and vascular leakage, raising the possibility that targeting this miRNA could support preservation of hepatic function.63 Similarly, miR-1303 has been linked to early plasma leakage and mild mucosal bleeding, indicating that inhibition could potentially reduce endothelial disruption.49 In contrast, several miRNAs are downregulated in SD and may be candidates for replacement strategies. miR-146a-5p is reduced in SD/DHF, and its inhibition has been associated with enhanced DENV-2–induced autophagy and inflammatory injury in hepatic tissue, suggesting that miR-146a-5p mimic therapy may help reduce inflammation and organ damage.63 miR-573 is downregulated in endothelial cells during DENV infection, and restoring its expression decreases endothelial permeability, supporting its therapeutic relevance for plasma leakage.55 miR-126-5p, which is reduced in DHF liver, is implicated in maintaining endothelial integrity and may likewise be a candidate for mimic-based approaches to limit vascular leakage.63 Additional candidates include hsa-miR-26b-5p and hsa-miR-335-5p, which are downregulated in SD and correlate with CXCR1 upregulation and inflammatory recruitment; restoring their levels may modulate immune cell infiltration.64 Finally, hsa-miR-30a-5p, hsa-miR-548c-5p, hsa-miR-548d-5p, and hsa-miR-652-3p have been proposed as regulators of FcγR-associated pathways, and modulating these miRNAs could directly affect ADE by reducing antibody-mediated viral uptake in monocytes.59
5.2. miRNA mimics and inhibitors: Prospects and limitations
Therapeutic modulation of miRNA activity can be achieved using miRNA mimics, which restore downregulated miRNAs, or miRNA inhibitors (e.g., antagomirs and locked nucleic acid-based oligonucleotides), which suppress overexpressed miRNAs.71 In dengue, inhibitor-based strategies have been proposed for miRNAs that rise in severe disease and are linked to inflammation and endothelial dysfunction, including miR-574-5p, miR-1246, miR-150-5p, miR-122-5p, and miR-1303. Conversely, mimic-based strategies may be appropriate for miRNAs with putatively protective roles that are reduced during SD, such as miR-146a-5p, miR-573, miR-126-5p, hsa-miR-26b-5p, and hsa-miR-335-5p, with the goal of restoring immune regulation and vascular integrity. Despite these prospects, several limitations remain, including pleiotropic effects, off-target interactions, and the need for careful target selection, dosing, and timing, since systemic modulation may influence both protective and pathogenic pathways depending on the disease phase and tissue context.42
5.3. Challenges for Clinical Translation of miRNA-Based Therapeutics
Although miRNA-based therapeutics have emerged as a promising strategy for the treatment of a wide range of diseases, their clinical translation remains challenging because of multi-target effects, delivery limitations, and safety concerns. The same characteristics that make miRNAs attractive therapeutic agents, their ability to regulate multiple genes and signaling pathways simultaneously, also introduce significant challenges related to pleiotropic effects, tissue-specific responses, and unpredictable toxicity.72,73
Unlike conventional drugs that typically target a single protein or pathway, individual miRNAs can regulate extensive gene networks. Consequently, therapeutic modulation of a single miRNA may influence numerous biological processes beyond the intended target pathway. This pleiotropic nature represents one of the major translational barriers to miRNA-based therapies. In addition to intended therapeutic effects, miRNA mimics or inhibitors may disrupt physiological cellular functions, alter tissue homeostasis, or produce unintended consequences in non-target tissues.72, 73, 74 Such concerns are particularly relevant in complex diseases such as dengue, where antiviral immunity, inflammation, endothelial integrity, and tissue repair mechanisms are closely interconnected.
Off-target effects present an additional challenge. Because miRNA–mRNA interactions often rely on partial sequence complementarity, therapeutic miRNAs may regulate unintended transcripts that were not predicted during the design phase. Furthermore, miRNA activity is influenced by cellular context, including tissue-specific expression patterns, Argonaute protein availability, target abundance, and interactions with competing endogenous RNAs. As a result, the biological effects observed in vitro may not accurately predict therapeutic outcomes in vivo.75, 76, 77, 78
Efficient and tissue-specific delivery remains one of the most significant obstacles to clinical application. Naked miRNA molecules are rapidly degraded in circulation and exhibit limited cellular uptake. Moreover, systemic administration may expose non-target tissues to therapeutic agents, increasing the risk of adverse effects. To overcome these limitations, various delivery platforms have been developed, including lipid nanoparticles, polymeric nanoparticles, and exosome-based delivery systems. These approaches can improve stability, biodistribution, and intracellular delivery, particularly in endothelial and immune cells implicated in dengue pathogenesis and ADE.79 The successful clinical implementation of lipid nanoparticle technologies in RNA-based therapeutics and vaccines highlights the translational potential of these delivery strategies.80 Nevertheless, delivery systems must achieve an optimal balance between stability, tissue penetration, intracellular release, immunogenicity, and toxicity.
The timing of therapeutic intervention represents another important challenge. miRNA expression patterns vary considerably across tissues and disease stages, and the biological consequences of a given miRNA mimic or inhibitor may differ depending on when treatment is administered.81 In dengue infection, therapeutic effects may vary substantially between the early phase of viral replication, the period of peak viremia, and the later inflammatory phase associated with severe disease and ADE. Consequently, defining appropriate therapeutic windows will be critical to maximize efficacy while minimizing interference with protective antiviral responses. In addition, prolonged tissue persistence and extended biological half-lives of some RNA-based therapeutics raise concerns regarding reversibility, dose optimization, and long-term safety.82,83 Future studies should therefore explore pharmacokinetic/pharmacodynamic-guided and biomarker-informed dosing strategies rather than relying solely on fixed empirical treatment schedules.
Immune-related adverse effects also require careful consideration. Both therapeutic miRNAs and their delivery vehicles may activate innate immune pathways or induce inflammatory responses. Furthermore, inhibition of miRNAs involved in host defense mechanisms could potentially compromise antiviral immunity, whereas excessive suppression of inflammatory pathways might impair viral clearance. These competing effects highlight the need for a balanced therapeutic approach that attenuates immunopathology without undermining protective immune responses.84,85
Taken together, miRNA-based therapies offer considerable promise as novel host-directed interventions for dengue and other infectious diseases. However, their successful clinical translation will require careful consideration of pleiotropic effects, tissue-specific responses, delivery barriers, treatment timing, and immune-related toxicities. Further preclinical studies and well-designed clinical trials are needed to establish the safety, efficacy, and optimal implementation of miRNA-based therapeutic strategies in dengue infection.
5.4. Personalized medicine and future research directions
Dengue outcomes vary across individuals due to viral serotype, infection history, host genetics, and immune status.86 miRNA expression profiles linked to ADE and SD may therefore enable patient stratification and support more personalized therapeutic strategies.14 Conceptually, patients with elevated ADE-associated miRNAs, such as miR-574-5p and miR-1246, may be candidates for inhibitor-based approaches, whereas those with downregulated protective miRNAs, such as miR-146a-5p or miR-573, may benefit from mimic-based restoration. Future research should focus on longitudinal profiling across disease phases, integration of miRNA signatures with clinical, immunological, and virological data, rigorous mechanistic validation in relevant human and animal systems, and well-designed clinical trials. Ultimately, miRNA modulation may complement antiviral drugs, immunomodulators, or vaccines as part of a comprehensive dengue management strategy.
6. Conclusion
Dengue severity is not determined solely by viral burden, but by the quality and regulation of the host immune response—particularly during ADE. Emerging evidence indicates that miRNAs are key modulators of this process, shaping FcγR signaling, inflammatory amplification, and endothelial dysfunction. Distinct miRNA signatures observed in severe and ADE-mediated dengue highlight their role in driving immune imbalance and vascular leakage.
Beyond their mechanistic relevance, several circulating miRNAs show promise as biomarkers for early risk stratification and disease monitoring. Although therapeutic modulation of miRNAs remains challenging, targeting dysregulated miRNA networks may offer a novel host-directed strategy to mitigate SD. A deeper integration of miRNA profiling with clinical and immunological data will be essential to translate these insights into practical diagnostic and therapeutic advances.
CRediT authorship contribution statement
Seyyedeh Fateme Babai: Writing – original draft. Mohammadmatin Nourikhani: Writing – original draft. Niloofar Farsiu: Writing – review & editing, Visualization. Fatemeh Khodadadpour Mahani: Writing – original draft. Arman Khajouei: Writing – original draft. Mohammad Rahimi: Writing – original draft. Saeedeh Tahroodi: Writing – original draft. Mohammad Rezaei Zadeh Rukerd: Writing – review & editing. Mohsen Nakhaie: Writing – review & editing, Supervision, Conceptualization.
Informed consent
Not applicable.
Organ Donation
Not applicable.
Ethical statement
Not applicable.
Data availability statement
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
Animal treatment
Not applicable.
Generative AI
We used ChatGPT (GPT-4, OpenAI, San Francisco, USA), accessed via the ChatGPT platform (https://chat.openai.com/), and QuillBot (v23.51.2, Learneo, Inc., San Francisco, USA), accessed via the QuillBot website (https://quillbot.com/). These tools were used to reduce the word count of certain sections, check grammar, and improve clarity and phrasing, without altering the scientific content or the originality of the ideas. Generative AI was used to assist in creating some small schematic icons and vector elements incorporated into the figures and graphical abstract. These individual elements were generated using ChatGPT (GPT-4). However, the figures and graphical abstract as a whole were not generated by AI.
Funding
The authors declare that no funding was received for this study.
Declarations of competing interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Acknowledgements
None.
Footnotes
Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.imj.2026.100295.
Appendix. Supplementary materials
References
- 1.Shepard D.S., Undurraga E.A., Betancourt-Cravioto M., et al. Approaches to refining estimates of global burden and economics of dengue. PLoS Negl Trop Dis. 2014;8(11) doi: 10.1371/journal.pntd.0003306. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Nakhaie M., Shahpar A., Rezaei Zadeh Rukerd M., et al. Dengue fever: viral, environmental, and human factors driving expansion and pandemic risk. Rev Med Virol. 2026;36 doi: 10.1002/rmv.70088. [DOI] [PubMed] [Google Scholar]
- 3.Farsiu N., Zandi K., Rukerd M.R.Z., et al. Challenges in the prevention and treatment of dengue fever: an emerging issue. Am J Trop Med Hyg. 2025;113(6):1185–1199. doi: 10.4269/ajtmh.25-0049. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Ramasamy R., Surendran S.N., Jude P.J., et al. Larval development of Aedes aegypti and Aedes albopictus in peri-urban brackish water and its implications for transmission of arboviral diseases. PLoS Negl Trop Dis. 2011;5(11) doi: 10.1371/journal.pntd.0001369. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Centers for Disease Control and Prevention. Dengue. CDC Yellow Book: Health Information for International Travel 2025. Accessed December 25, 2025. https://www.cdc.gov/yellow-book/hcp/travel-associated-infections-diseases/dengue.html. [PubMed]
- 6.World Health Organization. Dengue and severe dengue. World Health Organization. Updated August 21, 2025. Accessed September 16, 2024. https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue.
- 7.Murugesan A., Manoharan M. Emerging and Reemerging Viral Pathogens. Elsevier; Amsterdam: 2020. Dengue virus; pp. 281–359. [DOI] [Google Scholar]
- 8.Tamura T., Zhang J.Y., Madan V., et al. Generation and characterization of genetically and antigenically diverse infectious clones of dengue virus serotypes 1-4. Emerg Microbes Infect. 2022;11(1):227–239. doi: 10.1080/22221751.2021.2021808. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Zerfu B., Kassa T., Legesse M. Epidemiology, biology, pathogenesis, clinical manifestations, and diagnosis of dengue virus infection, and its trend in Ethiopia: a comprehensive literature review. Trop Med Health. 2023;51(1):11. doi: 10.1186/s41182-023-00504-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Horstick O., Jaenisch T., Martinez E., et al. Comparing the usefulness of the 1997 and 2009 WHO dengue case classification: a systematic literature review. Am Soc Trop Med Hyg. 2014;91(3):621–634. doi: 10.4269/ajtmh.13-0676. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Anam V., Guerrero B.V., Srivastav A.K., et al. Within-host models unravelling the dynamics of dengue reinfections. Infect Dis Model. 2024;9(2):458–473. doi: 10.1016/j.idm.2024.02.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Teo A., Chua C.L.L., Chia P.Y., et al. Insights into potential causes of vascular hyperpermeability in dengue. PLoS Pathog. 2021;17(12) doi: 10.1371/journal.ppat.1010065. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Macha N.O., Komarasamy T.V., Harun S., et al. Cross talk between microRNAs and dengue virus. Am J Trop Med Hyg. 2024;110(5):856–867. doi: 10.4269/ajtmh.23-0546. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Wong R.R., Abd-Aziz N., Affendi S., et al. Role of microRNAs in antiviral responses to dengue infection. J Biomed Sci. 2020;27(1):4. doi: 10.1186/s12929-019-0614-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Su Y.H., Lin T., Liu C., et al. microRNAs, the link between dengue virus and the host genome. Front Microbiol. 2021;12 doi: 10.3389/fmicb.2021.714409. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Roy S.K., Bhattacharjee S. Dengue virus: epidemiology, biology, and disease aetiology. Can J Microbiol. 2021;67(10):687–702. doi: 10.1139/cjm-2020-0572. [DOI] [PubMed] [Google Scholar]
- 17.World Health Organization (WHO) Revised and Expanded Edition. World Health Organization, Regional Office for South-East Asia; 2011. Comprehensive Guidelines for Prevention and Control of Dengue and Dengue Haemorrhagic Fever. [Google Scholar]; Accessed September 16, 2024. https://iris.who.int/items/f3f4cbe8-1718-40d2-a750-c4d9480e707b.
- 18.Yang Z.S., Baua A.D., Hemdan M.S., et al. Dengue virus infection: a systematic review of pathogenesis, diagnosis and management. J Infect Public Heal. 2025;18(12) doi: 10.1016/j.jiph.2025.102982. [DOI] [PubMed] [Google Scholar]
- 19.Priyadarshi M., Sikdar S., Brijwal M. Mosquito-Borne Tropical Diseases. IntechOpen; London: 2024. Immune response in dengue fever and clinical implications. [DOI] [Google Scholar]
- 20.Bournazos S., Gupta A., Ravetch J.V. The role of IgG Fc receptors in antibody-dependent enhancement. Nat Rev Immunol. 2020;20(10):633–643. doi: 10.1038/s41577-020-00410-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Junker F., Gordon J., Qureshi O. Fc gamma receptors and their role in antigen uptake, presentation, and T cell activation. Front Immunol. 2020;11:1393. doi: 10.3389/fimmu.2020.01393. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Teo A., Tan H.D., Loy T., et al. Understanding antibody-dependent enhancement in dengue: are afucosylated IgG1s a concern? PLoS Pathog. 2023;19(3) doi: 10.1371/journal.ppat.1011223. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Yamin R., Kao K.S., MacDonald M.R., et al. Human FcγRIIIa activation on splenic macrophages drives dengue pathogenesis in mice. Nat Microbiol. 2023;8(8):1468–1479. doi: 10.1038/s41564-023-01421-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Bournazos S., Vo H.T.M., Duong V., et al. Antibody fucosylation predicts disease severity in secondary dengue infection. Science. 2021;372(6546):1102–1105. doi: 10.1126/science.abc7303. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Katzelnick L.C., Gresh L., Halloran M.E., et al. Antibody-dependent enhancement of severe dengue disease in humans. Science. 2017;358(6365):929–932. doi: 10.1126/science.aan6836. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Balingit J.C., Abe M., Suzuki R., et al. Cross-genotype immunogenicity and antibody-dependent enhancement of KD-382 dengue vaccine in flavivirus-naïve adults. NPJ Vaccines. 2025;10(1):148. doi: 10.1038/s41541-025-01204-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Chelluboina S., Kshirsagar D., Panzade G., et al. Evaluation of methods for the measurement of antibody-dependent enhancement of dengue virus infection using different FcγRIIa expressing cell lines. PLoS One. 2025;20(8) doi: 10.1371/journal.pone.0331320. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Kayesh M.E.H., Tsukiyama-Kohara K. Mammalian animal models for dengue virus infection: a recent overview. Arch Virol. 2022;167(1):31–44. doi: 10.1007/s00705-021-05298-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Ripoll D.R., Wallqvist A., Chaudhury S. Molecular simulations reveal the role of antibody fine specificity and viral maturation state on antibody-dependent enhancement of infection in dengue virus. Front Cell Infect Microbiol. 2019;9:200. doi: 10.3389/fcimb.2019.00200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Sarker A., Dhama N., Gupta R.D. Dengue virus neutralizing antibody: a review of targets, cross-reactivity, and antibody-dependent enhancement. Front Immunol. 2023;14 doi: 10.3389/fimmu.2023.1200195. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Rodrigo WWSI, Block O.K.T., Lane C., et al. Dengue virus neutralization is modulated by IgG antibody subclass and fcγ receptor subtype. Virology. 2009;394(2):175–182. doi: 10.1016/j.virol.2009.09.024. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Thivierge C., Bellefeuille M., Diwan S.S., et al. Paraspeckle-independent co-transcriptional regulation of nuclear microRNA biogenesis by SFPQ. Cell Rep. 2024;43(9) doi: 10.1016/j.celrep.2024.114695. [DOI] [PubMed] [Google Scholar]
- 33.Herbert K.M., Sarkar S.K., Mills M., et al. A heterotrimer model of the complete Microprocessor complex revealed by single-molecule subunit counting. RNA. 2016;22(2):175–183. doi: 10.1261/rna.054684.115. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Kwon S.C., Nguyen T.A., Choi Y.G., et al. Structure of human DROSHA. Cell. 2016;164(1/2):81–90. doi: 10.1016/j.cell.2015.12.019. [DOI] [PubMed] [Google Scholar]
- 35.Nguyen T.A., Jo M.H., Choi Y.G., et al. Functional anatomy of the human microprocessor. Cell. 2015;161(6):1374–1387. doi: 10.1016/j.cell.2015.05.010. [DOI] [PubMed] [Google Scholar]
- 36.Lund E., Güttinger S., Calado A., et al. Nuclear export of microRNA precursors. Science. 2004;303(5654):95–98. doi: 10.1126/science.1090599. [DOI] [PubMed] [Google Scholar]
- 37.Yi R., Qin Y., Macara I.G., et al. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev. 2003;17(24):3011–3016. doi: 10.1101/gad.1158803. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Gebert L.F.R., MacRae I.J. Regulation of microRNA function in animals. Nat Rev Mol Cell Biol. 2019;20(1):21–37. doi: 10.1038/s41580-018-0045-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Chandan K., Gupta M., Sarwat M. Role of host and pathogen-derived microRNAs in immune regulation during infectious and inflammatory diseases. Front Immunol. 2019;10:3081. doi: 10.3389/fimmu.2019.03081. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Tuiskunen Bäck A., Lundkvist Å. Dengue viruses–an overview. Infect Ecol Epidemiol. 2013;3(1) doi: 10.3402/iee.v3i0.19839. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Curtale G., Rubino M., Locati M. microRNAs as molecular switches in macrophage activation. Front Immunol. 2019;10:799. doi: 10.3389/fimmu.2019.00799. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Girardi E., López P., Pfeffer S. On the importance of host microRNAs during viral infection. Front Genet. 2018;9:439. doi: 10.3389/fgene.2018.00439. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Li L.J., Xiang Y.T., Cai Y.J., et al. microRNAs as orchestrators of immune responses to bacterial infection. Microorganisms. 2026;14(3):515. doi: 10.3390/microorganisms14030515. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Xu S.J., Chen J.H., Chang S., et al. The role of miRNAs in T helper cell development, activation, fate decisions and tumor immunity. Front Immunol. 2023;14 doi: 10.3389/fimmu.2023.1320305. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Avila-Bonilla R.G., Yocupicio-Monroy M., Marchat L.A., et al. Analysis of the miRNA profile in C6/36 cells persistently infected with dengue virus type 2. Virus Res. 2017;232:139–151. doi: 10.1016/j.virusres.2017.03.005. [DOI] [PubMed] [Google Scholar]
- 46.Ouyang X.X., Jiang X., Gu D.Y., et al. Dysregulated serum MiRNA profile and promising biomarkers in dengue-infected patients. Int J Med Sci. 2016;13(3):195–205. doi: 10.7150/ijms.13996. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Saini J., Bandyopadhyay B., Pandey A.D., et al. High-throughput RNA sequencing analysis of plasma samples reveals circulating microRNA signatures with biomarker potential in dengue disease progression. mSystems. 2020;5(5) doi: 10.1128/mSystems.00724-20. e00724–e00720. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Tambyah P.A., Ching C.S., Sepramaniam S., et al. microRNA expression in blood of dengue patients. Ann Clin Biochem. 2016;53(Pt 4):466–476. doi: 10.1177/0004563215604001. [DOI] [PubMed] [Google Scholar]
- 49.Limothai U., Jantarangsi N., Suphavejkornkij N., et al. Discovery and validation of circulating miRNAs for the clinical prognosis of severe dengue. PLoS Negl Trop Dis. 2022;16(10) doi: 10.1371/journal.pntd.0010836. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Rothman A.L., Ennis F.A. Immunopathogenesis of dengue hemorrhagic fever. Virology. 1999;257(1):1–6. doi: 10.1006/viro.1999.9656. [DOI] [PubMed] [Google Scholar]
- 51.Pu J.Y., Wu S.Y., Xie H.P., et al. miR-146a inhibits dengue-virus-induced autophagy by targeting TRAF6. Arch Virol. 2017;162(12):3645–3659. doi: 10.1007/s00705-017-3516-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Wu S.Y., He L., Li Y.Y., et al. miR-146a facilitates replication of dengue virus by dampening interferon induction by targeting TRAF6. J Infect. 2013;67(4):329–341. doi: 10.1016/j.jinf.2013.05.003. [DOI] [PubMed] [Google Scholar]
- 53.Zhu X., He Z.J., Hu Y.W., et al. microRNA-30e* suppresses dengue virus replication by promoting NF-κb–dependent IFN production. PLoS Negl Trop Dis. 2014;8(8) doi: 10.1371/journal.pntd.0003088. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Apoorva K.A., Singh S.K. Dengue virus NS1 hits hard at the barrier integrity of human cerebral microvascular endothelial cells via cellular microRNA dysregulations. Tissue Barriers. 2025;13(3) doi: 10.1080/21688370.2024.2424628. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Banerjee S., Xin C.W., Chu J.J.H. microRNA 573 rescues endothelial dysfunction during dengue virus infection under PPARγ regulation. J Virol. 2022;96(6) doi: 10.1128/jvi.01996-21. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Fish J.E., Santoro M.M., Morton S.U., et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell. 2008;15(2):272–284. doi: 10.1016/j.devcel.2008.07.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Sriprapun M., Rattanamahaphoom J., Sriburin P., et al. The expression of circulating hsa-miR-126-3p in dengue-infected Thai pediatric patients. Pathog Glob Health. 2023;117(1):76–84. doi: 10.1080/20477724.2022.2088465. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Naqvi A.R., Fordham J.B., Nares S. microRNA target fc receptors to regulate Ab-dependent Ag uptake in primary macrophages and dendritic cells. Innate Immun. 2016;22(7):510–521. doi: 10.1177/1753425916661042. [DOI] [PubMed] [Google Scholar]
- 59.Rossi ÁD, Higa L.M., Herlinger A.L., et al. Differential expression of human microRNAs during dengue virus infection in THP-1 monocytes. Front Cell Infect Microbiol. 2021;11 doi: 10.3389/fcimb.2021.714088. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Vigorito E., Perks K.L., Abreu-Goodger C., et al. microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity. 2007;27(6):847–859. doi: 10.1016/j.immuni.2007.10.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Chen R.F., Yang K.D., Lee I.K., et al. Augmented miR-150 expression associated with depressed SOCS1 expression involved in dengue haemorrhagic fever. J Infect. 2014;69(4):366–374. doi: 10.1016/j.jinf.2014.05.013. [DOI] [PubMed] [Google Scholar]
- 62.Hapugaswatta H., Amarasena P., Premaratna R., et al. Differential expression of microRNA, miR-150 and enhancer of zeste homolog 2 (EZH2) in peripheral blood cells as early prognostic markers of severe forms of dengue. J Biomed Sci. 2020;27(1):25. doi: 10.1186/s12929-020-0620-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.de Oliveira L.F., de Andrade A.A.S., Pagliari C., et al. Differential expression analysis and profiling of hepatic miRNA and isomiRNA in dengue hemorrhagic fever. Sci Rep. 2021;11(1):5554. doi: 10.1038/s41598-020-72892-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Ferreira C.S., da Silva A.T., Brustolini O.J.B., et al. Immune and vascular modulation by HERVs: the role of CXCR1 and IL18RAP in dengue severity progression. Front Immunol. 2025;16 doi: 10.3389/fimmu.2025.1557588. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Naqvi A.R., Fordham J.B., Ganesh B., et al. miR-24, miR-30b and miR-142-3p interfere with antigen processing and presentation by primary macrophages and dendritic cells. Sci Rep. 2016;6(1) doi: 10.1038/srep32925. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Rajput R., Sharma J., Nair M.T., et al. Regulation of host innate immunity by non-coding RNAs during dengue virus infection. Front Cell Infect Microbiol. 2020;10 doi: 10.3389/fcimb.2020.588168. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Chan C.Y.Y., Low J.Z.H., Gan E.S., et al. Antibody-dependent dengue virus entry modulates cell intrinsic responses for enhanced infection. MSphere. 2019;4(5) doi: 10.1128/msphere.00528-19. e00528–e00519. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Gerasymchuk D., Hubiernatorova A., Domanskyi A. microRNAs regulating cytoskeleton dynamics, endocytosis, and cell motility-a link between neurodegeneration and cancer? Front Neurol. 2020;11 doi: 10.3389/fneur.2020.549006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Lee M.F., Wu Y.S., Poh C.L. Molecular mechanisms of antiviral agents against dengue virus. Viruses. 2023;15(3):705. doi: 10.3390/v15030705. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Bahojb Mahdavi S.Z., Jebelli A., Aghbash P.S., et al. A comprehensive overview on the crosstalk between microRNAs and viral pathogenesis and infection. Med Res Rev. 2025;45(2):349–425. doi: 10.1002/med.22073. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Holjencin C., Jakymiw A. microRNAs and their big therapeutic impacts: delivery strategies for cancer intervention. Cells. 2022;11(15):2332. doi: 10.3390/cells11152332. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Diener C., Keller A., Meese E. Emerging concepts of miRNA therapeutics: from cells to clinic. Trends Genet. 2022;38(6):613–626. doi: 10.1016/j.tig.2022.02.006. [DOI] [PubMed] [Google Scholar]
- 73.Seyhan A.A. Trials and tribulations of microRNA therapeutics. Int J Mol Sci. 2024;25(3):1469. doi: 10.3390/ijms25031469. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Zhang S., Cheng Z.J., Wang Y.N., et al. The risks of miRNA therapeutics: in a drug target perspective. DDDT. 2021;15:721–733. doi: 10.2147/dDDT.s288859. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Momin M.Y., Gaddam R.R., Kravitz M., et al. The challenges and opportunities in the development of microRNA therapeutics: a multidisciplinary viewpoint. Cells. 2021;10(11):3097. doi: 10.3390/cells10113097. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76.Pandey S., Yadav P. Exploring the therapeutic potential of microRNAs: targeted gene regulation strategies for enhanced cancer therapy. J Genet Eng Biotechnol. 2025;23(4) doi: 10.1016/j.jgeb.2025.100556. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77.Bereczki Z., Benczik B., Balogh O.M., et al. Mitigating off-target effects of small RNAs: conventional approaches, network theory and artificial intelligence. British J Pharmacology. 2025;182(2):340–379. doi: 10.1111/bph.17302. [DOI] [PubMed] [Google Scholar]
- 78.Qian H.B., Maghsoudloo M., Kaboli P.J., et al. Decoding the promise and challenges of miRNA-based cancer therapies: an essential update on miR-21, miR-34, and miR-155. Int J Med Sci. 2024;21(14):2781–2798. doi: 10.7150/ijms.102123. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79.Segal M., Slack F.J. Challenges identifying efficacious miRNA therapeutics for cancer. Expert Opin Drug Discov. 2020;15(9):987–991. doi: 10.1080/17460441.2020.1765770. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80.Reda El Sayed S., Cristante J., Guyon L., et al. microRNA therapeutics in cancer: current advances and challenges. Cancers. 2021;13(11):2680. doi: 10.3390/cancers13112680. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81.Dasgupta I., Chatterjee A. Recent advances in miRNA delivery systems. Methods Protoc. 2021;4(1):10. doi: 10.3390/mps4010010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82.Di Martino M.T., Tagliaferri P., Tassone P. microRNA in cancer therapy: breakthroughs and challenges in early clinical applications. J Exp Clin Cancer Res. 2025;44(1):126. doi: 10.1186/s13046-025-03391-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 83.Vélez-Slimani H., Salazar L.A. Therapeutic microRNAs: mechanisms, delivery, and clinical translation in oncology. Int J Mol Sci. 2026;27(5):2162. doi: 10.3390/ijms27052162. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 84.Ahmed J.Q., Maulud S.Q., Dhawan M., et al. microRNAs in the development of potential therapeutic targets against COVID-19: a narrative review. J Infect Public Heal. 2022;15(7):788–799. doi: 10.1016/j.jiph.2022.06.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 85.Wang Z.Y., Peng Y.Y., Zhou H.F., et al. MiRNA-based drugs: challenges and delivery strategies. Appl Microbiol Biotechnol. 2025;109(1):247. doi: 10.1007/s00253-025-13620-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86.Bhatt P., Sabeena S.P., Varma M., et al. Current understanding of the pathogenesis of dengue virus infection. Curr Microbiol. 2021;78(1):17–32. doi: 10.1007/s00284-020-02284-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
